Turkovac

❧

Wikipedia

Turkovac
Vaccine description
TargetSARS-CoV-2
Vaccine typeInactivated
Clinical data
Other namesErucov-Vac
Routes of
administration		Intramuscular
Legal status
Legal status
Identifiers
CAS Number

Turkovac[2] (pronunciation: ['tɜ:rkəvæk]) is a COVID-19 vaccine developed by Turkish Ministry of Health and Erciyes University.

Clinical trials

In November 2020, Turkovac started on phase I trials with 44 participants in Turkey.[3]

In February 2021, Turkovac started on phase II trials with 250 participants in Turkey.[4]

In June 2021, Turkovac started on phase III trials with 40,800 participants in Turkey.[5] As of 2023 phase III trials continue.[6]

Authorization

On 25 November 2021, the Turkish Minister of Health reported that Turkovac's application for emergency use authorization had been filed.[7] On 22 December, Turkish President Recep Tayyip Erdogan announced the emergency use approval of Turkovac.[8]

References

  1. ↑ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
  2. ↑ Cakmak BN (22 June 2021). "Turkey names home-grown COVID-19 jab Turkovac". Anadolu Agency.
  3. ↑ Clinical trial number NCT04691947 for "Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine Erucov-Vac" at ClinicalTrials.gov
  4. ↑ Clinical trial number NCT04824391 for "Efficacy, Immunogenicity and Safety of Inactivated Erucov-Vac Compared With Placebo in COVID-19 " at ClinicalTrials.gov
  5. ↑ "Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (Turkovac) Versus the CoronaVac Vaccine". ClinicalTrials.gov. 28 June 2021. NCT04942405. Retrieved 29 June 2021.
  6. ↑ "ClinicalTrials.gov". www.clinicaltrials.gov. Retrieved 16 January 2024.
  7. ↑ "Turkey issues emergency-use authorization for its domestically produced vaccine". The New York Times. 22 December 2021. Retrieved 28 December 2021.
  8. ↑ "Turkey authorises use of own Turkovac Covid-19 vaccine". France 24. 23 December 2021. Retrieved 24 December 2021.